Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.

Mitomycin plus BCG is as safe and effective as BCG alone, but the combination allows for a reduction in BCG doses and may help combat the BCG shortage.

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

Adding rusfertide to standard care can reduce the need for phlebotomy and improve symptoms in patients with polycythemia vera who require frequent phlebotomies, data suggest.

Adjuvant cemiplimab improved DFS in patients with CSCC who had completed adjuvant radiotherapy and had a high risk of recurrence.

Zanubrutinib plus venetoclax elicited durable responses in patients with treatment-naïve CLL or SLL and high-risk genetic features.

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high risk of relapse.

Adding tagitanlimab to treatment with gemcitabine and cisplatin improved PFS in patients with recurrent or metastatic nasopharyngeal cancer.

A reflex ctDNA-methylation MCED test can detect multiple cancer types in patients with obesity, a new study suggests.

A training platform integrated with AI can help pathologists identify HER2-low and HER2-ultralow breast cancers with more accuracy, data suggest.

Escalating adjuvant treatment based on ctDNA positivity does not improve RFS in patients with stage III colon cancer, data suggest.